BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to one new employee. The grant was offered as material inducement to the employee’s employment with Amwell. The RSUs will vest as follows, subject to the employee’s continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date (“Ini ...

CareCloud (CCLD) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Ladies and gentlemen, greetings, and welcome to the CareCloud, Inc. First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Kristen Rotti, Corporate Counsel. Please go ahead. Speaker1 Good morning, everyone. W ...

RESULTS NASDAQ GLOBAL MARKET: CCLD, CCLDO A healthcare technology company with 25 years of experience, delivering AI-driven, end-to-end solutions that power real-world clinical and financial transformation. © CareCloud, Inc. 2025 This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by ...

Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]

Core Insights - Aclarion, Inc. announced the addition of Advocate Aurora Research Institute as a site for the CLARITY trial, which aims to demonstrate the clinical and economic value of its Nociscan platform in spine surgery [1][4][5] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][5][8] - The Nociscan platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [5][8] CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain [4] - The trial will randomize patients at a 1:1 ratio between surgeons blinded to Nociscan results and those unblinded, with the primary endpoint being the change in back pain measured on a 100mm VAS at 12 months [4][5] - The principal investigator is Dr. Nicholas Theodore from Johns Hopkins Medicine [4] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting a significant healthcare challenge [5] - Traditional imaging methods often fail to clearly identify the source of pain, which Nociscan aims to address by providing insights into disc pain [5][8]

New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions (25% lower) in heart failure patientsWILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablem ...

Core Insights - OptimizeRx Corp. has published its 2025 Environmental, Social, and Governance (ESG) report, highlighting its commitment to corporate responsibility and stakeholder engagement [1][3] - The company improved its Institutional Shareholder Services (ISS) ESG rating from the seventh decile to the first decile, achieving prime status [3] Governance - The Board of Directors and the Nominating & Governance Committee are actively involved in aligning business strategies with corporate governance policies [8] - A double-materiality survey identified key stakeholder concerns in three areas: Data Protection, Ethics and Governance, and Human Capital [8] Planet - The 2025 ESG report includes enhanced disclosures on Scope 1 emissions and additional reporting on individual greenhouse gases [5] People - The company emphasizes impartiality in employment practices and aims to foster a culture of respect and inclusivity [9] - Initiatives such as the SPARK employee recognition program and a Competency Model have been introduced to enhance employee engagement and career progression [9] Prosperity - The Dynamic Audience Activation Platform (DAAP) has seen strong adoption, providing AI-enabled marketing solutions that connect life sciences, healthcare professionals, and patients [15] - The integration of Healthy Offers, Inc. enhances the company's data and analytics capabilities, expanding its stakeholder engagement [15]

NAPLES, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp (OTCQB: HLYK) today announced a major enhancement to its appointment booking capabilities, further expanding patient access to care across its growing network of healthcare providers. The latest upgrade makes it easier than ever for patients to discover and schedule appointments directly through the HealthLynked app and platform. Building upon the prior functionality where users could search for specific providers and book appointme ...

Spok (SPOK) Q1 2025 Earnings Call April 30, 2025 05:00 PM ET Speaker0 Greetings, and welcome to Spok's First Quarter twenty twenty five Earnings Results Conference Call. At this time, participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Al Galgano. Thank you. You may begin. ...

Waystar Holding (WAY) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Sandy Draper - VP, Investor RelationsMatt Hawkins - CEO & Board MemberSteve Oreskovich - CFOAdam Hotchkiss - VP - Emerging Software Equity ResearchSaket Kalia - Managing DirectorBrian Peterson - Managing DirectorJailendra Singh - Managing DirectorRyan Daniels - Group Head–Healthcare Technology and ServicesRichard Close - Managing DirectorAnne Samuel - Executive Director Conference Call Participants Joanna Zhou - Equi ...